Braveheart Bio Stock Forecast
NASDAQ: BRVEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 20.02 0.00%
BRVE analyst consensus
Consensus (5 analysts)
strong_buy
Avg. price target
$45.25+126.02%
- Strong buy 0
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 5 Wall Street analysts covering Braveheart Bio (2026-10-07), 5 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $45.25, with a high estimate of $48.00 and a low estimate of $40.00. The average target implies upside of 126.0% from the current price of $20.02.
The spread between the highest and lowest targets is 20.0%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for BRVE.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 5 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $40.00 | +99.80% |
| Average target | $45.25 | +126.02% |
| High target | $48.00 | +139.76% |